AUTOLUS LIMITED
A wholly owned subsidiary of the NASDAQ-listed Autolus Therapeutics plc, the company is a clinical-stage biopharmaceutical business developing programmed CAR T cell therapies for the treatment of cancer and autoimmune diseases.
Get an alert when AUTOLUS LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£167M
-3.2% vs 2023
Net assets
-£323M
-370.7% vs 2023
Employees
441
+11.4% vs 2023
Profit before tax
-£180M
+4.5% vs 2023
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Negative shareholders' funds
Net assets
2-year trend · vs Health Care median
Accounts
2-year trend · Δ = latest vs prior filed period · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 | Δ vs prior |
|---|---|---|---|---|
| Turnover | £397,000 | £7,981,000 | +1,910.3% | |
| Operating profit | -£162,508,000 | -£194,425,000 | -19.6% | |
| Profit before tax | -£188,904,000 | -£180,461,000 | +4.5% | |
| Net profit | -£173,057,000 | -£166,656,000 | +3.7% | |
| Cash | £172,755,000 | £167,216,000 | -3.2% | |
| Total assets less current liabilities | — | — | — | |
| Net assets | -£68,648,000 | -£323,101,000 | -370.7% | |
| Equity | -£68,648,000 | -£323,101,000 | -370.7% | |
| Average employees | 396 | 441 | +11.4% | |
| Wages | £34,201,000 | £37,160,000 | +8.7% | |
| Directors' remuneration | £1,223,000 | £1,135,000 | -7.2% |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Gearing (liabilities / total assets) | 124.4% | 151.2% | |
| Current ratio | 4.88x | 7.27x | |
| Interest cover | -4.17x | -17.89x |
Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.
Name history
Renamed 1 time since incorporation
- AUTOLUS LIMITED 2014-08-21 → present
- NEWINCCO 1311 LIMITED 2014-07-03 → 2014-08-21
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- Ernst & Young LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period to 30 September 2026.”
Significant events
- “FDA approved AUCATZYL (obecabtagene autoleucel) on 8 November 2024.”
- “Commercial launch and first sale of AUCATZYL in the United States occurred in January 2025.”
- “MHRA granted AUCATZYL conditional marketing authorization in April 2025 for UK.”
- “European Commission granted marketing authorization for AUCATZYL in July 2025 for EU.”
- “Entered into a strategic collaboration agreement and equity investment with BioNTech SE in February 2024.”
- “Paid UCLB a regulatory milestone payment of £10.0 million upon FDA approval of AUCATZYL.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 19 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| OAKWOOD CORPORATE SECRETARY LIMITED | Corporate Secretary | 2022-03-08 | — | — |
| MCILVENNY, Patrick Paul | Director | 2025-09-02 | May 1978 | Irish |
| WILLIAMS, Christopher Michael James | Director | 2025-09-02 | Feb 1980 | British |
Show 19 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| OLSWANG COSEC LIMITED | Corporate Secretary | 2014-07-03 | 2022-03-08 |
| ALDER, Matthias | Director | 2018-06-22 | 2021-09-30 |
| ANDERSON, Joe | Director | 2016-03-02 | 2018-06-15 |
| BERRIMAN, John | Director | 2014-10-20 | 2018-06-15 |
| BRADSHAW, John | Director | 2014-08-21 | 2014-09-24 |
| BUTITTA, Cynthia Marie | Director | 2018-03-08 | 2018-06-15 |
| CRABTREE, Lucinda Claire, Dr. | Director | 2022-10-13 | 2023-08-02 |
| DHINGRA, Kapil | Director | 2014-10-20 | 2018-06-15 |
| HODGKIN, Edward Eliot | Director | 2014-09-25 | 2018-06-15 |
| ITIN, Christian Martin | Director | 2014-10-20 | 2026-02-12 |
| MACKIE, Christopher Alan | Director | 2014-07-03 | 2014-08-21 |
| MERCIECA, Andrew Paul | Director | 2023-08-02 | 2025-08-08 |
| MORELAND, Dominic Michael | Director | 2018-06-22 | 2021-05-31 |
| MURPHY, Martin Patrick | Director | 2014-09-25 | 2018-06-22 |
| OAKLEY, Andrew John, Mr. | Director | 2021-05-31 | 2022-10-13 |
| PULE, Martin, Dr | Director | 2014-09-24 | 2018-06-15 |
| WILLIAMS, Chris | Director | 2014-09-25 | 2016-07-07 |
| OLSWANG DIRECTORS 1 LIMITED | Corporate Director | 2014-07-03 | 2014-08-21 |
| OLSWANG DIRECTORS 2 LIMITED | Corporate Director | 2014-07-03 | 2014-08-21 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Autolus Holdings (Uk) Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2018-06-15 | Active |
| Syncona Limited | Corporate entity | Shares 25–50%, Voting 50–75% | 2017-02-22 | Ceased 2018-06-15 |
| Syncona Llp | Corporate entity | Shares 50–75%, Voting 50–75% | 2016-04-06 | Ceased 2017-02-22 |
Filing timeline
Last 20 of 129 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-02-20 | TM01 | officers | Termination director company with name termination date | |
| 2025-09-23 | AA | accounts | Accounts with accounts type full | |
| 2025-09-05 | RP04AP01 | officers | Second filing of director appointment with name | |
| 2025-09-05 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-09-05 | RP04AP01 | officers | Second filing of director appointment with name | |
| 2025-09-03 | AP01 | officers | Appoint person director company with name date | |
| 2025-09-03 | AP01 | officers | Appoint person director company with name date | |
| 2025-08-15 | TM01 | officers | Termination director company with name termination date | |
| 2025-03-28 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2024-10-12 | AA | accounts | Accounts with accounts type full | |
| 2024-09-12 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-02-20 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2023-09-25 | CH01 | officers | Change person director company with change date | |
| 2023-09-18 | AA | accounts | Accounts with accounts type full | |
| 2023-09-14 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-08-02 | AP01 | officers | Appoint person director company with name date | |
| 2023-08-02 | TM01 | officers | Termination director company with name termination date | |
| 2023-01-11 | AP01 | officers | Appoint person director company with name date | |
| 2023-01-11 | TM01 | officers | Termination director company with name termination date | |
| 2022-09-14 | AA | accounts | Accounts with accounts type full |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 8
- Capital events
- 0
- Officers appointed
- 2
- Officers resigned
- 2
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.